UP-pharma is the first GxP contract research organization in China. The company provides the-state-of-art high-tech platforms, for pharmacokinetics, bioanalysis, and toxicology, to support new drug development under a regulated (FDA and EMEA regulations) environment. Currently, it supports 70% macromolecule compound in PK studies in China.

UP-pharma has an excellent scientific and business team with highly motivation for innovation. The main senior managers have been educated and trained in USA and European countries. All senior managers have extensive business experiences in their field. We have established a powerful service cooperation network to many established domestic organizations and the talent pool in China. UP-pharma also offers global broad and integrated portfolio of laboratory and research manufacturing services ranging from discovery chemistry to biological services.

UP-pharma is located in Zhong-guan-cun(ZGC) Life Science Park, which is a professional science park developed by the Beijing Municipal Government. The testing facility is well-positioned to offer its customers high quality services along the drug discovery value chain.

UP-pharma continues to make changes to strengthen the company's position to be a leading innovator in global life sciences markets. The company is executing a growth strategy that focuses exclusively on opportunities within the fast growing life sciences markets served by the Company's three core businesses on Late-Stage Drug Development: Pharmacokinetics and Toxicokinetics, and Bioanalysis.